Revvity (NYSE:RVTY) Downgraded by Wall Street Zen to "Hold"

Key Points

• Wall Street Zen downgraded Revvity to “Hold” from “Buy,” aligning with the broader analyst consensus. MarketBeat reports three Buy ratings and 12 Hold ratings, with an average price target of $108.36.
• Revvity’s latest quarterly results exceeded expectations, with EPS of $1.41 versus $1.21 estimated and revenue of $729.69 million versus $702.96 million expected. However, revenue declined 1.3% year over year, and the company guided to fiscal 2026 EPS of $5.30–$5.40.
• The stock opened at $116.71, near its 52-week high of $118.34, while institutional investors own 86.65% of outstanding shares.

Revvity (NYSE:RVTY - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Sunday.

RVTY has been the topic of a number of other research reports. Evercore reaffirmed an "outperform" rating on shares of Revvity in a report on Wednesday, August 5th. Wolfe Research started coverage on Revvity in a research report on Tuesday, June 2nd. They issued a "peer perform" rating for the company. Barclays boosted their target price on Revvity from $95.00 to $105.00 and gave the company an "equal weight" rating in a research note on Thursday, May 7th. TD Cowen reaffirmed a "buy" rating on shares of Revvity in a research report on Wednesday, July 15th. Finally, Sanford C. Bernstein assumed coverage on Revvity in a research note on Friday, June 26th. They set a "market perform" rating and a $115.00 price target for the company. Three analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat.com, Revvity presently has a consensus rating of "Hold" and a consensus target price of $108.36.

Revvity Stock Performance

NYSE RVTY opened at $116.71 on Friday. Revvity has a 52-week low of $81.22 and a 52-week high of $118.34. The company has a 50-day simple moving average of $109.62 and a 200 day simple moving average of $100.09. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The company has a market capitalization of $13.02 billion, a PE ratio of 55.58, a price-to-earnings-growth ratio of 2.13 and a beta of 1.07.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. During the same quarter in the previous year, the firm posted $1.18 earnings per share. The company's revenue for the quarter was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts predict that Revvity will post 5.36 EPS for the current year.

Hedge Funds Weigh In On Revvity

A number of institutional investors have recently added to or reduced their stakes in the business. EdgePoint Investment Group Inc. boosted its position in shares of Revvity by 3.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company's stock valued at $771,044,000 after acquiring an additional 265,204 shares during the last quarter. Jupiter Topco LLC purchased a new position in shares of Revvity during the second quarter worth about $961,017,000. Price T Rowe Associates Inc. MD increased its position in shares of Revvity by 5.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,606,637 shares of the company's stock worth $832,693,000 after purchasing an additional 434,570 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Revvity by 2.3% in the first quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company's stock worth $731,386,000 after purchasing an additional 186,956 shares during the last quarter. Finally, BlackRock Inc. purchased a new stake in Revvity in the second quarter valued at approximately $852,070,000. 86.65% of the stock is currently owned by institutional investors.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source